Ad
related to: bicalutamide monotherapy wikipedia magyar tvgoodrx.com has been visited by 100K+ users in the past month
- Free Discount Card
Get a Free Discount Card Today and
Start Saving up to 80% Off Your Rx
- GoodRx® For Pets
GoodRx® Loves Your Pets Too!
Discover Big Savings on Pet Meds
- Flu Shot & Med Discounts
Get a Free Discount for Your
Flu Shot or Prescriptions
- Phone Support Available
Our dedicated customer support team
is here to help answer questions.
- Free Discount Card
Search results
Results from the WOW.Com Content Network
Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. [10] It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC).
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
However, bicalutamide is the most potent of the three, with the highest affinity for the AR [23] [24] and the longest elimination half-life, [10] and is the safest, least toxic, and best-tolerated. [25] For these reasons, bicalutamide has largely replaced flutamide and nilutamide in clinical use, [26] and is by far the most widely used first ...
It has also been reported that bicalutamide monotherapy decreases median circulating levels of PSA at 3 months by 86.7% at 100 mg/day, 91.1% at 150 mg/day, and 93.8% at 200 mg/day (relative to 94–97% for castration). [56] Above a bicalutamide monotherapy dosage of 200 mg/day, up to 600 mg/day, decreases in PSA levels reach a plateau.
The EPC programme found that bicalutamide was effective in treating locally advanced prostate cancer. [2] Conversely, it was not effective for localized prostate cancer, where there was instead a statistically insignificant trend toward reduced overall survival with bicalutamide therapy (at median 7.4 years follow-up: HR Tooltip hazard ratio ...
In the EPC trial, in which bicalutamide monotherapy (150 mg/day) was evaluated for treatment of early prostate cancer in 8,113 men, the incidence of abnormal liver function tests at 3-year median follow-up was 3.4% for bicalutamide plus standard care (n=4,052) and 1.9% for standard care alone (n=4,061).
[16] [20] Monotherapy with the nonsteroidal antiandrogen bicalutamide is also used in the treatment of prostate cancer as an alternative to castration with comparable effectiveness but with a different and potentially advantageous side effect profile. [16] [21] [22] High-dose estrogen was the first functional antiandrogen used to treat prostate ...
Bicalutamide (Casodex): Marketed for the treatment of prostate cancer and also used in the treatment of hirsutism in women, [4] as a component of hormone therapy for transgender women, [5] to delay precocious puberty in boys, [7] to prevent or alleviate priapism, [8] and for other indications.
Ad
related to: bicalutamide monotherapy wikipedia magyar tvgoodrx.com has been visited by 100K+ users in the past month